Stockholm - Free Realtime Quote SEK

SpectrumOne AB (publ) (SPEONE.ST)

0.2630

-0.0060

(-2.23%)

As of 3:39:25 PM GMT+2. Market Open.

Tesla EU sales, FDA & Moderna, DraftKings: Trending Tickers

Tesla (TSLA) sales were mixed in Europe during May. Its sales in Norway more than tripled, while sales in France, Sweden, Denmark, the Netherlands, and Spain declined. The US Food and Drug Administration (FDA) approved Moderna's (MRNA) new COVID-19 vaccine, sending the pharmaceutical giant's stock higher. DraftKings (DKNG) stock is under pressure following news that Two Sigma Advisers lowered its stake in the company and after Illinois lawmakers passed a sports-betting tax increase. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 20 minutes ago

TSLA

MRNA

DKNG
Sanofi to expand immunology offerings with Blueprint Medicines

Sanofi has committed to pay $129 per share in cash on closure.

Pharmaceutical Technology 4 minutes ago

SNY

BPMC
Another Way To Trade Broadcom Stock Ahead Of This Week's Earnings

Broadcom stock has a history of performing well during earnings in recent years, recording only a couple of large declines.

Investor's Business Daily 12 minutes ago

AVGO
Google to spend $500 million revamping compliance in shareholder settlement

(Reuters) -Google agreed to spend $500 million over 10 years to overhaul its compliance structure, to settle shareholder litigation accusing the search engine company of antitrust violations, settlement papers show. The preliminary settlement of so-called derivative litigation against officials at Google parent Alphabet, including Chief Executive Sundar Pichai and Google co-founders Sergey Brin and Larry Page, was filed late Friday. The changes include creating a standalone board committee to oversee risk and compliance, previously the responsibility of the Alphabet board's audit and compliance committee.

Reuters 24 minutes ago

GOOG
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response

Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings significantly surpassed the company’s expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release. Pharmacokinetics (PK): KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. Rapid absorp

Benzinga 29 minutes ago

KYMR

REGN
BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration with Bristol Myers Squibb.

Investopedia 42 minutes ago

BNTX

CELG-RT
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement. The pact focuses on BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and Bristol Myers Squibb will work jointly to broaden and accelerate the development of this clinical candidate. Also Read: BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expa

Benzinga 45 minutes ago

BNTX

CELG-RT
Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

Blueprint Medicines Blueprint Medicines stock was soaring Monday after French drugmaker Sanofi said it had agreed to buy the biotech company for $9.5 billion. Sanofi’s American depositary receipts slipped 0.4%. Sanofi is paying $129 a share in cash at closing, and Blueprint shareholders will also receive a nontradeable contingent value right that will entitle them to payments worth up to $6 a share if certain milestones are met.

Barrons.com 1 hour ago

BPMC

SNY
These Stocks Are Moving the Most Today: Cleveland-Cliffs, Tesla, Blueprint Medicines, Moderna, BioNTech, DraftKings, and More

Shares of steel companies soar after President Donald Trump says he will raise tariffs on imported steel to 50% from 25%.

Barrons.com 1 hour ago

STLD

MRNA

BPMC
Boeing upgraded, PayPal initiated: Wall Street's top analyst calls

Boeing upgraded, PayPal initiated: Wall Street's top analyst calls

The Fly 1 hour ago

BA

TFC

PYPL
Cleveland-Cliffs Stock, Other Steel Shares Soar on Trump’s Bombshell Steel Tariff Announcement

President Trump said tariffs on imported steel would go to 50% from 25%. That has investors excited early Monday.

Barrons.com 1 hour ago

X

STLD
Sanofi to Acquire Blueprint Medicines for up to $9.5 Billion to Expand Immunology Portfolio

Sanofi (SNY) agreed to acquire biopharmaceutical company Blueprint Medicines (BPMC) in a deal worth

PREMIUM
MT Newswires 1 hour ago

SNY

BPMC
Alphabet stock falls on monopoly case uncertainties

Investing.com -- Shares of Alphabet Inc. (NASDAQ:GOOGL) fell 2% as the outcome of a federal antitrust case remains uncertain. During a recent hearing, U.S. District Judge Amit Mehta indicated he might consider less stringent measures than those proposed by the Department of Justice (DOJ) to address Google’s dominance in online search and advertising.

Investing.com 1 hour ago

GOOG
Nucor Leads S&P 500 On Trump's 50% Steel, Aluminum Tariffs

President Donald Trump's Friday announcement that steel and aluminum tariffs will double to 50% on June 4 sent shares of U.S. producers surging early Monday, including Nucor, Cleveland-Cliffs and Century Aluminum. Trump made the announcement at a Friday rally near Pittsburgh, celebrating Nippon Steel's deal to buy U.S. Steel, which he blessed after the Japanese company pledged to build a new mill and double its spending plan. "Nobody's going to get around that," Trump said Friday, in announcing the 50% steel tariff.

Investor's Business Daily 1 hour ago

CLF

X

CENX
Broadcom (AVGO) Q2 Earnings Preview: What to Expect From Upcoming Report

Broadcom Eyes a Major Surge as Q2 Profit Forecast Ignites Investor Frenzy

GuruFocus.com 1 hour ago

AVGO

NVDA
UnitedHealth Declines 40.4% YTD: Here's Why it's Still Not a Bargain

UNH shares have plunged YTD, but regulatory risks, cost pressures and earnings downgrades keep it far from a bargain.

Zacks 1 hour ago

UNH
Alphabet Inc. (GOOGL) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Alphabet (GOOGL). This makes it worthwhile to examine what the stock has in store.

Zacks 1 hour ago

GOOG
Is Trending Stock Palantir Technologies Inc. (PLTR) a Buy Now?

Zacks.com users have recently been watching Palantir Technologies (PLTR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks 1 hour ago

PLTR
Is UnitedHealth Group (NYSE:UNH) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Simply Wall St. 1 hour ago

UNH
Is Trending Stock Alphabet Inc. (GOOG) a Buy Now?

Zacks.com users have recently been watching Alphabet (GOOG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks 1 hour ago

GOOG

Performance Overview

Return	SPEONE.ST	OMX Stockholm 30 Index (^OMX)
YTD	+6.48%	-0.06%
1-Year	-51.30%	-4.70%
3-Year	-76.09%	+19.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SpectrumOne AB (publ) (SPEONE.ST)

Related News

Tesla EU sales, FDA & Moderna, DraftKings: Trending Tickers

Sanofi to expand immunology offerings with Blueprint Medicines

Another Way To Trade Broadcom Stock Ahead Of This Week's Earnings

Google to spend $500 million revamping compliance in shareholder settlement

Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response

BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration

Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal.

These Stocks Are Moving the Most Today: Cleveland-Cliffs, Tesla, Blueprint Medicines, Moderna, BioNTech, DraftKings, and More

Boeing upgraded, PayPal initiated: Wall Street's top analyst calls

Cleveland-Cliffs Stock, Other Steel Shares Soar on Trump’s Bombshell Steel Tariff Announcement

Sanofi to Acquire Blueprint Medicines for up to $9.5 Billion to Expand Immunology Portfolio

Alphabet stock falls on monopoly case uncertainties

Nucor Leads S&P 500 On Trump's 50% Steel, Aluminum Tariffs

Broadcom (AVGO) Q2 Earnings Preview: What to Expect From Upcoming Report

UnitedHealth Declines 40.4% YTD: Here's Why it's Still Not a Bargain

Alphabet Inc. (GOOGL) is Attracting Investor Attention: Here is What You Should Know

Is Trending Stock Palantir Technologies Inc. (PLTR) a Buy Now?

Is UnitedHealth Group (NYSE:UNH) A Risky Investment?

Is Trending Stock Alphabet Inc. (GOOG) a Buy Now?

Performance Overview